- 22 Jan 2019
Alvotech has raised $300 million through a private bond offering to fuel continued growth, refinance of existing debt and the further development of Alvotech’s biosimilar assets.
- 22 Jan 2019
Wren Therapeutics has cashed in £18 million from an international syndicate led by The Baupost Group, in a Series A financing round, which also included LifeForce Capital and a number of high net worth individual investors, the company said Tuesday.
- 22 Jan 2019
TWi Biotechnology has enrolled patients in its Phase 2 clinical trial of AC-203 for the treatment of inherited Epidermolysis Bullosa (EB).
- 22 Jan 2019
- 21 Jan 2019
Vertex Pharmaceuticals Limitedgot will extend label for its cystic fibrosis children patients treatment Orkambi in Europe, after the Union’s Commissions’ approval.
- 21 Jan 2019
Taisho Pharmaceutical Holdings has offered to purchase Bristol-Myers Squibb’s UPSA consumer health business for $1.6 billion, Bristol-Myers Squibb said in a statement on Saturday.
- 21 Jan 2019
The UK market focused joint venture between Canopy Growth Corporation and Beckley Canopy Therapeutics will exclusively distribute Cannabis medicinal products of newly formed, built-for-purpose distribution company that will introduce Spectrum Cannabis medicinal cannabis products to UK patients and doctors.
- 21 Jan 2019
Redx got back on track to resume clinical evaluation of RXC004 in patients with advanced solid tumours in the first half of 2019.
My Pharmaceutical
Consequences of microbead: What makes microbeads problematic
In the world of great discoveries that cure or add a positive element to our everyday existence, the invention of microbeads hasn’t proven to be one of them. Not alone in its quick rise to popularity and slow journey to extinction, the microbead is just one of numerous products rushed to market before its long term effects are uncovered.
